Search Results
Sep 18, 2025, 13:23 ET LabConnect Appoints Bill Finger as Senior Vice President, Global Strategic Services
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Sep 18, 2025, 12:52 ET LabConnect Appoints Bill Finger as Senior Vice President, Global Strategic Services
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Sep 18, 2025, 10:01 ET Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Surges to USD 60.3 Billion by 2033, Propelled by 7.3% CAGR - Verified Market Reports®
Organization (CDMO) Outsourcing Market: Trends and Opportunities Biologics-first demand surge: Rapid growth in cell & gene therapies, monoclonal antibodies, and personalized biologics is shifting capacity demand from small-molecule CMOs to CDMOs with advanced bioprocess
More news about: Verified Market Reports
Sep 18, 2025, 09:15 ET Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting
More news about: Illumina, Inc.
Sep 18, 2025, 09:10 ET Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
dosed 15 participants in its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 gene therapy targeting Duchenne muscular dystrophy, with the treatment continuing to be well tolerated and no treatment emergent serious adverse events observed.
More news about: USA News Group
Sep 18, 2025, 08:46 ET Akadeum Life Sciences Human T Cell Leukopak Isolation Kit Successfully Utilized by LEAH Labs and the University of Missouri to Treat Canine Cancer
resolution of internal disease indicated by X-ray and ultrasound imaging. PET imaging technology further demonstrated the ability to visualize the gene-edited CAR T cells in injected lymph nodes. All data will be available in the upcoming publication in progress by the group. The findings are
More news about: Akadeum Life Sciences
Sep 18, 2025, 08:45 ET Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
the market. Innovations in technologies like gene editing, gene modification, and viral vectors are enhancing the effectiveness of cell therapies. These technologies further accelerate the production of
More news about: MarketNewsUpdates
Sep 18, 2025, 08:00 ET Artistic Milliners Acquires Majority Stake in Cone Denim
standards in responsible manufacturing and Cone's commitment to making a positive impact in its communities. From performance denims and superior S GENE® technology to vintage re-creations of Cone Deeptone Denim™ reaching back to the early 1900s, Cone offers unique collections of Performance,
More news about: Elevate Textiles
Sep 18, 2025, 06:00 ET PlantArcBio Secures U.S. and South Korea Patents for DIPPER™ Platform, Advancing Gene-Editing Optimization in Crops
States and South Korea for its proprietary DIPPER™ platform, a breakthrough technology designed to optimize gene expression for gene-editing processes in crops.
More news about: PlantArcBio
Sep 17, 2025, 15:25 ET The fifth Guangdong-Hong Kong-Macao Greater Bay Area Culture and Arts Festival opens
events will be held. The festival began with the "Symphony of the Greater Bay Area" concert, where seven compositions highlighting the "GBA gene"—Guangdong's most outstanding original symphonic works from recent years—were performed. Multiple world-renowned classic works will be staged in the
More news about: Guangdong Province
Sep 17, 2025, 15:16 ET The fifth Guangdong-Hong Kong-Macao Greater Bay Area Culture and Arts Festival opens
events will be held. The festival began with the "Symphony of the Greater Bay Area" concert, where seven compositions highlighting the "GBA gene"—Guangdong's most outstanding original symphonic works from recent years—were performed. Multiple world-renowned classic works will be staged in the
More news about: Guangdong Province
Sep 17, 2025, 14:47 ET Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome
exercise or emotional stress. The three most common subtypes of congenital LQTS are Type 1, Type 2, and Type 3, each caused by distinct ion channel gene mutations that influence the specific triggers for arrhythmic events. In addition to the congenital forms, LQTS may also be acquired, most often due
More news about: Thryv Therapeutics Inc.
Sep 17, 2025, 11:03 ET Landmark UCSF Study Demonstrates Functional Rescue of SCN2A Loss of Function, Underscoring the Potential of Regel Therapeutics' Targeted EpiEditing Platform.
Targeted EpiEditing platform, designed to restore normal gene expression exclusively in the cells affected by disease. The platform delivers a deactivated Cas9 system under the control of proprietary cell-specific promoters, enabling durable rescue of gene expression with minimal off-target effects. Regel's
More news about: Regel Therapeutics Inc.
Sep 17, 2025, 10:37 ET 'Functional Unemployment' Drops Slightly, But Labor Market Remains Weak, Says Ludwig Institute
@LISEP_org. About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder
More news about: Ludwig Institute for Shared Economic Prosperity
Sep 17, 2025, 09:00 ET Mana.bio Unveils Mina™,The World's First Large Language Model-Powered AI Agent for Lipid Nanoparticles
"ChatGPT for LNPs" - is publicly available at no cost, marking a significant step forward in accelerating scientific discovery and advancing the future of gene therapy and RNA-based medicines.
More news about: Mana.bio
Sep 17, 2025, 09:00 ET Mana.bio Unveils Mina™,The World's First Large Language Model-Powered AI Agent for Lipid Nanoparticles
for LNPs" - is publicly available at no cost, marking a significant step forward in accelerating scientific discovery and advancing the future of gene therapy and RNA-based medicines.
More news about: Mana.bio
Sep 17, 2025, 08:00 ET Study Published in the Journal Infection Demonstrates Clinical Utility of SeptiCyte® RAPID to Diagnose Sepsis in Critically Ill Patients with Hospital Acquired Infections
sepsis, which is often difficult to diagnose due to overlapping inflammation from initial pathology, invasive devices, and noninfectious complications. Gene host response assessment proved effective in detecting sepsis in critically ill patients with nosocomial infections," commented Paula Ramírez Galleymore,
More news about: Immunexpress, Inc.
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
FDA. About ARTHEx Biotech ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform pairs selective oligonucleotides with tissue-specific delivery to reach skeletal muscle, heart, and brain. Its
More news about: ARTHEx Biotech
Sep 16, 2025, 17:31 ET KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight
Oncology KAT6 inhibitors represent a new class of epigenetic therapeutics, offering a novel approach to cancer treatment. Their ability to modulate gene expression through histone acetylation makes them valuable in targeting cancers with dysregulated epigenetic landscapes Robust KAT6 Inhibitors
More news about: DelveInsight Business Research, LLP
Sep 16, 2025, 12:05 ET Inari Announces New Chief Commercial Officer, Rob Dunlop
what is possible for a more sustainable, nature-positive food system. Through a combination of AI-enabled predictive design and a leading multiplex gene editing toolbox, the company is unlocking the full potential of seed to bring step-change soybean, corn and wheat products to market. Founded by Flagship
More news about: Inari
Sep 16, 2025, 10:06 ET Promising New Preclinical Therapy Offers Hope in the Development of Precision Medicine Treatments for Aggressive Cancers
Therapeutics Program at CHOP's Cancer Center, and her team are renowned for the groundbreaking discovery of gain-of-function mutations in the ALK gene, which are the primary cause of hereditary neuroblastoma and the most common mutations in its sporadic forms. This discovery was pivotal as it identifies
More news about: Children's Hospital of Philadelphia
Sep 16, 2025, 09:00 ET Multicare Pharma anuncia acordo de distribuição exclusiva de medicamento para tratamento de Distrofia Muscular de Duchenne no Brasil
Muscular de Duchenne A distrofia muscular de Duchenne (DMD) é um distúrbio neuromuscular raro e progressivo causado por mutações no gene DMD. Mutações no gene DMD impedem a produção de distrofina funcional, fazendo com que o complexo proteico associado à distrofina (DAPC) se decomponha. Isso torna
More news about: Multicare Pharma
Sep 16, 2025, 08:30 ET Barron Prize Celebrates 25 Years of Honoring Young Heroes Who Are Making a Difference
passionate about using molecular biology to develop new and affordable treatments for neurodegenerative and metabolic diseases. She has designed a novel gene-set profiling algorithm to explore specific cellular mechanisms that can be regulated to alleviate mitochondrial dysfunction -- the root of many diseases.
More news about: Gloria Barron Prize for Young Heroes
Sep 16, 2025, 08:11 ET Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
(MYR-101) is the first-ever recombinant AAV gene therapy designed to target oligodendrocytes, the brain cells responsible for producing myelin. The therapy directly addresses the enzymatic deficiency caused by mutations in the ASPA gene, which leads to impaired metabolism of N-acetylaspartate
More news about: Myrtelle, Inc
Sep 16, 2025, 07:33 ET Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Solutions